Silkworm Infection Models for Drug Discovery and Immunological Studies

Silkworm (Bombyx mori) larvae have emerged as versatile invertebrate infection models for preclinical evaluation of antimicrobial and immunomodulatory compounds. These models combine ethical and economic advantages with conserved aspects of innate immunity and pharmacokinetics that mirror those of mammalian systems. Infection of silkworms with bacteria or fungi elicits humoral and cellular responses, including the production of antimicrobial peptides, cytokine-like paralytic peptides and reactive oxygen species. The ease of genetic manipulation, rapid life cycle and low maintenance cost enable high-throughput screening of candidate drugs. In parallel, the distribution of drug-metabolising enzymes such as cytochrome P450 in the silkworm midgut offers insights into absorption, half-life and metabolic clearance. Beyond antimicrobial discovery, specialised silkworm models have been adapted to study hyperglycaemia and hyperlipidaemia for anti-diabetic drug screening. Collectively, silkworm infection models bridge the gap between in vitro assays and mammalian testing, accelerating the identification of novel therapeutics while reducing reliance on vertebrate subjects.

Research from Nature Portfolio

Recent investigations have delineated the pharmacokinetic fidelity of silkworms to mammals, demonstrating that drug half-lives, volumes of distribution and protein-binding characteristics in hemolymph closely parallel those in rodent or human plasma. Distribution of cytochrome P450 enzymes in the midgut governs metabolic clearance, with many compounds metabolised in human liver also processed similarly in silkworms. In structure-activity studies, optimisation of a nitroaromatic antimicrobial scaffold yielded candidates with enhanced half-life, low clearance and superior therapeutic indices in the silkworm model. These findings validate the predictive value of silkworm pharmacokinetics for downstream mammalian efficacy and support their use in early-stage drug development.

Silkworm Infection Models for Drug Discovery and Immunological Studies publication trend

The graph below shows the total number of articles in silkworm infection models for drug discovery and immunological studies across all publications each year (not limited to Nature Index journals).

Technical terms

Hemolymph: The circulatory fluid of insects, equivalent to blood in vertebrates.

Pharmacokinetics: The study of a compound’s absorption, distribution, metabolism and excretion.

Antimicrobial peptides: Endogenous small proteins that disrupt microbial membranes or inhibit growth.

Peptidoglycan: A mesh-like polymer forming the bacterial cell wall, recognised by innate immune receptors.

References

1. Advantages of the Silkworm As an Animal Model for Developing Novel Antimicrobial Agents. Frontiers in Microbiology (2017).
2. Insect Cytokine Paralytic Peptide (PP) Induces Cellular and Humoral Immune Responses in the Silkworm Bombyx mori *. Journal of Biological Chemistry (2010).
3. Activation of the Silkworm Cytokine by Bacterial and Fungal Cell Wall Components via a Reactive Oxygen Species-triggered Mechanism*. Journal of Biological Chemistry (2007).
4. Pharmacokinetics of anti-infectious reagents in silkworms. Scientific Reports (2019).
5. Pharmacokinetic parameters explain the therapeutic activity of antimicrobial agents in a silkworm infection model. Scientific Reports (2018).
6. An Invertebrate Hyperglycemic Model for the Identification of Anti-Diabetic Drugs. PLOS ONE (2011).
7. Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes. Scientific Reports (2015).
8. Primed Immune Responses Triggered by Ingested Bacteria Lead to Systemic Infection Tolerance in Silkworms. PLOS ONE (2015).
9. Primed Immune Responses to Gram-negative Peptidoglycans Confer Infection Resistance in Silkworms*. Journal of Biological Chemistry (2014).